Cardiology

Lp(a) is one of the biggest contributors to cardiovascular disease, but recent studies have shown that awareness of and testing for the condition is subpar nationwide.

A recent secondary analysis of the HELIOS-B trial has highlighted vutrisiran’s effects on atrial myopathy in patients with ATTR-CM.

Remick discusses multidisciplinary teams, adherence issues, and the path forward for heart failure care in this post-forum interview.

Philippe Généreux, MD, discusses a secondary analysis of EARLY TAVR examining patients excluded from the trial for positive treadmill stress tests.

The FDA approved a single-use autoinjector for lerodalcibep-liga alongside an updated lerodalcibep-liga indication reflecting MACE risk reduction from LDL-C lowering with statins or add-on PCSK9 inhibitors.

Karen Alexander, MD, discusses the recent statement evaluating the interconnected relationship between biological aging and cardiovascular risk.

Kriti Puri, MBBS, and colleagues have developed a preliminary definition and treatment strategy for this underrepresented disease.

Ronald D'Agostino, DO, discusses the 2026 HFpEF pathway, H2FPEF screening, and comorbidity-first heart failure care.

Experts discussed FCS diagnostic scoring tools, diagnostic delays, and new data on olezarsen and plozasiran for lowering triglycerides in a recent clinical forum.

A pair of clinical forums examined new CKM staging, SGLT2 and MRA trial data, and the barriers delaying heart failure treatment.

Get ahead of the curve with the top 6 trials to watch ahead of ESC 2026.

Phase 3 LEVEL trial of TNX-103 missed its primary 6MWD endpoint in PH-HFpEF, though a sicker patient subgroup showed benefit versus placebo.

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.

Examining individual pregnancy outcomes rather than defining women by the presence or absence of complications more reliably predicts later CVD death.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia and the FDA approval of Furoscix ReadyFlow.

July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!

All cardiovascular disease risks decreased proportionately across all quintiles of diet consistency, according to recent data.

John Giacona, PhD, PA-C, discusses building a comprehensive multidisciplinary care team for interstitial lung disease and how APPs should engage with clinical evidence.

The IL-6 inhibitor missed its primary MACE endpoint in ASCVD, CKD, and inflammation despite expected biological effect on target engagement.

The ACC's new decision pathway incorporates SGLT2 inhibitor finerenone and data on incretin therapy into HFpEF diagnosis and management guidance.

Benjamin van Boxtel, MD, discusses the importance of familial screening for aortic dissection and the danger of missing potential risk factors.

John Giacona, PhD, PA-C, discusses the cardiology perspective on screening for and managing pulmonary hypertension in interstitial lung disease.

CaRi-Heart measures coronary inflammation from routine CT angiography and generates a personalized 10-year cardiovascular mortality risk score.

Phoenix PAH specialists discuss RHC-guided monitoring, sotatercept shunting and erythrocytosis signals, meth-PAH management, and prostacyclin transition strategies.